IFNA1 and perivascular space measurement: PVS prevalence was lower in patients with early IFN therapy among both early and late GC users, while early IFN therapy had an even lower OR among early GC users (OR [95% CI], 0.15 [0.06–0.41] vs 0.25 [0.07–0.81]) (Fig. 3e, f).